🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

6,867 results for “De” Clear

  1. Doripenem

    Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

    Ventilator-Associated Pneumonia

    phase 3 small molecule terminated

    1 trial
  2. Double-blind, randomised clinical study comparing efficacy and safety of Mecloderm® Cream (Test) vs. Lotricomb® Cream (Reference) vs. Vehicle in patients with moderate to severely inflamed candidiasis of the skin

    Alphapharm Pty Ltd

    moderate to severely inflamed candidiasis of the skin

    phase 3 other active

    1 trial
  3. Dovato 50 mg/300 mg film-coated tablets, Biktarvy 50 mg/200 mg/25 mg film-coated tablets

    ViiV Healthcare Pty Ltd

    Human immunodeficiency virus (HIV)

    phase 3 small molecule active

    1 trial
  4. Dovato 50 mg/300 mg film-coated tablets, Truvada 200 mg/245 mg film-coated tablets, Descovy 200 mg/25 mg film-coated tablets, Combivir 150 mg/300 mg film-coated tablets, Epivir 300 mg film-coated tablets, Ziagen 300 mg film-coated tablets, Retrovir 250 mg capsules, hard, Kivexa 600 mg/300 mg film-coated tablets, Triumeq 50 mg/600 mg/300 mg film-coated tablets

    Fondazione Telethon ETS

    HIV-infected

    phase 3 small molecule active

    1 trial
  5. Doxorubicinhydrochlorid Teva® 2 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Bleomycin 15000 IU Powder for solution for injection/infusion, Detimedac 200 mg, Pulver zur Herstellung einer Injektions-/Infusionslösung, Doxorubicin hydrochloride 2 mg/ml solution for infusion, ADCETRIS 50 mg powder for concentrate for solution for infusion, Vinblastine Sulfate 1 mg/ml solution for injection, Dacarbazine medac 200 mg, powder for solution for injection/infusion, Vinblastinsulfat Teva® 1 mg/ml Injektions

    Takeda

    Advanced Classical Hodgkin Lymphoma

    phase 3 small molecule active

    1 trial
  6. Doxycycline

    United Therapeutics Europe Ltd

    Lymphedema

    phase 3 small molecule completed

    3 trials
  7. Dronabinol

    BRIGHT MINDS BIOSCIENCES INC.

    Cannabis Dependence

    phase 3 small molecule completed

    1 trial
  8. Dronabinol Capsules

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid Use Disorder

    phase 3 small molecule active

    1 trial
  9. Duloxetine hydrochloride

    Eli Lilly and Company

    Diabetic Neuropathies

    phase 3 small molecule completed

    1 trial
  10. Dupilumab SAR231893

    Regeneron UK Limited

    Neurodermatitis

    phase 3 small molecule completed

    2 trials
  11. Dupilumab, Matched placebo for test product

    Sanofi-aventis Healthcare Pty Ltd

    Neurodermatitis

    phase 3 small molecule active

    1 trial
  12. Dupilumab, Matched placebo for test product

    Sanofi-aventis Healthcare Pty Ltd

    Neurodermatitis

    phase 3 small molecule active

    1 trial
  13. Dupixent 200 mg solution for injection in pre-filled syringe, Dupixent 300 mg solution for injection in pre-filled pen, Dupixent 300 mg solution for injection in pre-filled syringe, Dupixent 200 mg solution for injection in pre-filled pen

    Lacuna Pharma Pty Ltd

    Atopic Dermatitis

    phase 3 small molecule active

    1 trial
  14. Durvalumab

    AstraZeneca

    Muscle Invasive Bladder Cancer

    phase 3 small molecule active

    1 trial
  15. Dynepo (Epoetin delta)

    Takeda

    Anemia

    phase 3 small molecule terminated

    1 trial
  16. Dysport Placebo Solution for injection, Botulinum Toxin Type A 500 units Powder for solution for injection, Botulinum Toxin Type A 300 units Powder for solution for injection

    Ipsen

    Chronic migraine

    phase 3 small molecule active

    1 trial
  17. Dysport Placebo Solution for injection, Botulinum Toxin Type A 300 units Powder for solution for injection, Botulinum Toxin Type A 500 units Powder for solution for injection

    Ipsen

    Episodic Migraine

    phase 3 small molecule active

    1 trial
  18. E/C/F/TDF

    Gilead Sciences Ireland UC

    Acquired Immunodeficiency Syndrome

    phase 3 small molecule completed

    1 trial
  19. EADM

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Carcinoma, Hepatocellular

    phase 3 small molecule active

    1 trial
  20. EB-101

    ABEONA THERAPEUTICS INC.

    Epidermolysis Bullosa

    phase 3 mab completed

    1 trial
  21. EB-101 Surgical application of RDEB wounds

    ABEONA THERAPEUTICS INC.

    Epidermolysis Bullosa

    phase 3 mab active

    1 trial
  22. ELECTROLYTES , DURVALUMAB, VASOPRESSIN (ARGIPRESSIN) , PREDNISOLONE , INFLIXIMAB, MYCOPHENOLATE MOFETIL, PARACETAMOL , Tarlatamab, Tarlatamab, TOCILIZUMAB, ETOPOSIDE, DEXAMETHASONE, SILTUXIMAB, CARBOPLATIN, CISPLATIN

    Amgen

    Extensive stage small cell lung cancer (ES-SCLC)

    phase 3 small molecule active

    1 trial
  23. ELIGARD 45 mg, poudre et solvant pour solution injectable

    Ningbo Cancer Hospital

    Prostatic adenocarnicoma with high risk of recurrence

    phase 3 small molecule active

    1 trial
  24. EMB-Fatol® 100 mg, Tabletten, The placebo for Amikacin Liposome for Inhalation Suspension drug product is a white translucent suspension consisting of dipalmitoylphosphatidylcholine (DPPC) and cholesterol, which are dispersed in 1.5% (w/w) sodium chloride solution. The placebo is filled into the same container closure system of the drug product, Azithromycin-ratiopharm 250mg Filmtabletten, Azithromycin STADA® 250 mg Filmtabletten, Azithromycin AL 250 mg Filmtabletten, Azitromicina Teva 250 mg comprimidos re

    Insmed Limited

    "Adult Subjects with Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium avium Complex (MAC)"

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources